Icono-regulatory

Establish the Right Regulatory Strategy by Relying on Clinical Development Experts

The Regulatory Strategy Is the Best Pathway to Draw Up Suitable Clinical Development Plans.

The experience of Asphalion’s clinical development team allows the selection of best regulatory strategy from all existing possibilities.

Strategic inputs can be given from the very beginning for segmentation/niche indication, conditional approval/fast track, orphan drug designations, preclinical and clinical development plans with minimum time-to-market, and others.

Regulatory Strategy Roadmaps

Non-clinical and clinical development plans, including assessment of feasibility, strategy, timelines and costs

Scientific Advice EMA, EU-NCAs and FDA

Regulatory strategy expertise for optimal outcome with EMA, EU-NCAs, FDA and other agencies

  • Paediatric Investigation Plan (PIP)
  • Orphan Drug Designation (ODD)
  • Clinical Trial Application (CTA)
  • Investigational Medicinal Product Dossier (IMPD)
  • Investigator’s Brochure (IB)
  • Regulatory Partner for Horizon 2020 Programme

Why Choose Asphalion to Handle your Regulatory Strategy and Clinical Development Plans?

Asphalion has already worked in 15 successful PIPs and 20 ODDs, along with Parallel FDA and EU submission for Fast Track / Conditional Approval. Our regulatory strategy experts have participated in Scientific advice with EMA as well as National Competent Authorities such as, PEI, AEMPS, DKMA, CbG, MPA, among others. We have been involved in the UAT of EMA for the new CT portal, and worked with EudraCT  and clinicaltrials.gov.

Besides, Asphalion has already been involved in 10 EU H2020 funded projects: iHIVARNA, MYOCURE, ELASTISLET, iHIVACAR, nTRACK, CardioReGenix, SBR , MISTRAL, VASCOVID and ARDAT.

Do you need support or more information about our regulatory strategy services? Contact us!




    I want to receive news and communications from Asphalion. yesno


    RELATED NEWS AND EVENTS

    WEBINAR | Cell Therapy – TRAcking, Circulation, & Safety (CT-TRACS) Committee Regulatory Perspectives

    The HESI Cell Therapy – TRAcking, Circulation, & Safety (CT-TRACS) Committee will present a webinar featuring four expert speakers who will share regulatory perspectives from both sides of the Atlantic. One of them will be Marta Rayo Lunar, Regulatory and Scientific Affairs Director at Asphalion.

    BIOSPAIN2021 | Roundtable

    BioSpain, the largest country-based biotech event in Europe will be held in Pamplona and online this year.Our expert, Lidia Cánovas, General Manager, Regulatory Affairs at Asphalion, will be participating in a roundtable during the event together with four other experts.

    AWARENESS | WORLD ALZHEIMER´S DAY

    World Alzheimer’s Day was launched in 1994 to mark the 10th anniversary of Alzheimer’s Disease International (ADI) and World Alzheimer’s Month a decade ago, and both have grown significantly since then.

    AWARENESS | WORLD PATIENT SAFETY DAY

    World Patient Safety Day was established to enhance global understanding of patient safety, increase public engagement in the safety of health care and promote global actions to enhance patient safety and reduce patient harm.

    BIOSPAIN2021 | Event and partnering

    ASPHALION experts Lidia Cánovas, OriolPenon, Marta Rayo Lunar and Cindy Mancia will attend the congress and will be more than happy to schedule a meeting with you to present you ASPHALION and all the solutions we can provide you with, as well as to discuss all your regulatory needs.